Predicting response to chemotherapy using gene expression markers
US7930104B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 4, 2005 |
| Grant date | Apr 19, 2011 |
| Priority date | — |
| Expiry date | Aug 16, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16B25/00
- WIPO fieldComputer technology
- WIPO sectorElectrical engineering
Abstract
The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.